Loading…
← CockpitCompetitor Analysis › AVTX Avalo Therapeutics IncOpen in the cockpit ↗

Avalo Therapeutics IncAVTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 3
Mkt cap
$387M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$24.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-174.7 pp
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · USD$6.70
1D-6.0%
1W-21.3%
1M-45.8%
3M-66.2%
6M-58.9%
YTD-63.1%
1Y-60.3%
ATR %12.0%
Beta1.47
52w lowhigh72.4% off high

What Avalo Therapeutics does

Employees: 33

Avalo Therapeutics at a glance

Size Avalo Therapeutics (AVTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 2854th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.70 on 18 Nov 2026.

Performance Over six months the shares fell 58.9%, against -17.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.

Growth Revenue fell 69.3% over the last twelve months (peer median -8.0%); the operating margin is -161,961.0% (peer median -7.8%).

Capital Return on invested capital runs 174.7 points below its cost of capital (8.9% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 83AVTX 40
Six months, rebased to 100: Avalo Therapeutics against the median of its 20 peers (local-currency closes).

Avalo Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$59,000$59,000$441,000$1.92M$18.1M
Revenue growth—-87%-77%-89%—
Gross profit-$9,000-$285,000$638,000$640,000$14.6M
EBITDA-$95.5M-$72.6M-$40.7M-$23.3M-$37.3M
Net income-$88.7M-$78.3M-$35.1M-$31.5M-$41.7M
Free cash flow-$63.5M-$51.5M-$49.1M-$30.8M-$26.8M
Capital expenditure$0$0$0$158,000$95,000
Total debt$2.15M$2.43M$2.92M$3.90M$23.7M

Quarterly statements and history in the cockpit →

Avalo Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%42C3004523005344592002868219A4552IRD300636688399PBYI0025810028726535MPLTAVTX6-month return →1-month return →
Up and to the right = strong over both horizons. Avalo Therapeutics is the large dot.

Avalo Therapeutics competitors and peer comparison

How Avalo Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Avalo Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureAVTXPeer medianRank in peer set
1-month return-45.8%-11.2%lowest of 20
6-month return-58.9%-17.8%2nd lowest of 19
Distance from 52-week high-72.4%-38.8%2nd lowest of 21
Revenue growth (TTM)-69.3%-8.0%lowest of 18
Operating margin-161,961.0%-7.8%lowest of 19
ROIC minus cost of capital-174.7 pp-2.5 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a

Questions

Which companies are Avalo Therapeutics's closest peers?
The cockpit's peer set: iX Biopharma (42C.SI), Shukra Pharmaceuticals (SHUKRAPHAR.NS), Anhui Sunhere Pharmaceutical Excipients (300452.SZ), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), SanBio (4592.T), Lifecome Biochemistry (002868.SZ), Heartseed (219A.T), JCR Pharmaceuticals (4552.T).
How has Avalo Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -58.9% against -17.8% for the median peer; over one year -60.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.